Alexandra Rojek

Heme/Onc Instructor @UCCancerCenter and @KlineLabUChi - lymphomas and cellular therapy. Views are my own.

[Alexandra Rojek @AlexandraRojek]

Very honored to receive this award alongside such incredible colleagues @AAnandappa and @Charlie_S_Dai, and excited for the promise of better understanding responses to cell therapy made possible by it! @KlineLabUChi @UChicagoHemOnc

[Damon Runyon Cancer Research Foundation @DamonRunyon]

Three clinicians with exceptional promise and novel approaches to fighting cancer have been named the 2025 recipients of the Damon Runyon Physician-Scientist Training Award.

[Alexandra Rojek @AlexandraRojek]

@ktsanov @AAnandappa @Charlie_S_Dai @KlineLabUChi @UChicagoHemOnc Thanks Kal! :)

[Alexandra Rojek @AlexandraRojek]

Very honored to receive this award alongside such incredible colleagues @AAnandappa and @Charlie_S_Dai, and excited for the promise of better understanding responses to cell therapy made possible by it! @KlineLabUChi @UChicagoHemOnc

[Damon Runyon Cancer Research Foundation @DamonRunyon]

Three clinicians with exceptional promise and novel approaches to fighting cancer have been named the 2025 recipients of the Damon Runyon Physician-Scientist Training Award.

[Alexandra Rojek @AlexandraRojek]

@SLentzsch @AAnandappa @Charlie_S_Dai @KlineLabUChi @UChicagoHemOnc Thank you, Dr. Lentzsch!! :)

[University of Chicago Hematology/Oncology @UChicagoHemOnc]

ASCO ended over a week ago, but we're still thinking about how great it was! Highlights included:
-@SoniSmithMD's first @ASCO conference on the Board of Directors
-4 (!!) of our @UCHemOncFellows winning YIAs
-@RitaNandaMD as a FASCO recipient
-30+ posters/presentations!

[Ajay Major, MD, MBA @majorajay]

From @KlineLabUChi in @BloodJournal: multi-omic characterization of 4 'immune quadrants' in DLBCL, with better response to bispecifics (but not CAR-T) in "GCB Hot" versus "GCB Cold." #lymsm #tcellrx https://t.co/6661CxpQMU

[University of Chicago Hematology/Oncology @UChicagoHemOnc]

Congratulations to our Section Chief, Dr. @SoniSmithMD new electee to the @ASCO Board of Directors as the Designated Medical Oncologist!! We see her dedicated & positive leadership daily & know how deserving she is of this honor! More from ASCO at https://t.co/23Pgnf214l

[Alexandra Rojek @AlexandraRojek]

along with an excellent editorial featuring this report and other work published examining outcomes from an EBMT study and the overlap and differences therein https://t.co/dEYc6UOar6

[Alexandra Rojek @AlexandraRojek]

Take a listen to my latest @JCO_ASCO Article Insights podcast on a @CIBMTR analysis of HLA-mismatched unrelated donors receiving PTCy with important implications for availability of donors for pts of minority ancestry https://t.co/c3Xqu6B7SM

[Alexandra Rojek @AlexandraRojek]

This original article confirms findings from randomized studies on GVHD-prophylaxis strategies to improve long-term pt outcomes, particularly for patients with HLA-mismatched donors available, which are more common among minority ancestry patients https://t.co/sJwqSDEFwM

[Jonathan Friedberg @DrJFriedberg]

Amazing collaborations in this successful @theNCI study led by Dr. Herrera. @SWOG @eaonc @COGorg @CDNCancerTrials @ALLIANCE_org Inclusive study enrolling pts aged 12+ with remarkable efficacy across all analyzed subgroups. Best-ever reported US results. https://t.co/aglB3gAWdl

[Kline Lab @KlineLabUChi]

We’re excited to see outstanding science talks at the Jonas Center for Cellular Therapy Symposium today @UChicagoHemOnc and updates on our lab’s work shared by Dr. Kline!

[Anand Patel @Anand_88_Patel]

The final version of our @e_JHaem paper on intensive chemo strategies in CBF-AML is available! @AlexandraRojek #leusm

-3y OS 70% and 3y EFS 51% for entire cohort
-IC + GO 3y EFS 50%, IC alone 3y EFS 47%, IC + KIT inhibitor 3y EFS 85%

https://t.co/KG1ntvgqqP

[Anand Patel @Anand_88_Patel]

Our analysis of intensive chemo (IC) in CBF-AML (200 pt) is out in @e_JHaem! Kudos to lead author @AlexandraRojek

We found:
-similar EFS/OS betw IC + GO & IC alone
-longer 3y EFS w/ IC + KIT inhibitor (85%)

we eagerly await NCT02013648 results!

https://t.co/KG1ntvfSBh

[Alexandra Rojek @AlexandraRojek]

An amazing start to #AACRMBCO24 with @UCHemOncFellows colleagues focusing on translational science in oncology! With some gorgeous summer days and scenery as a bonus 😎 @AACR @UChicagoHemOnc @cannova_joe @theproffermd

[Barry Butler Photography @barrybutler9]

Triple Strike at 1221am on Monday morning. Simultaneous lightning strikes on the Hancock, Trump Chicago and Sears Tower in Chicago. One image. #weather #news #ilwx #chicago #storm

[Alexandra Rojek @AlexandraRojek]

@your_hemoncdoc Thanks, Faith! :)

[Journal of Clinical Oncology @JCO_ASCO]

#JCO welcomes our onboarding editorial fellows, Ayse Ece Cali Daylan, @MSHughes_MD, Peter Li, Joseph Mathew & @lcshihmd!

[Alexandra Rojek @AlexandraRojek]

@Eddie_Cliff @UChicagoHemOnc @UCHemOncFellows thanks, Eddie!!

[Alexandra Rojek @AlexandraRojek]

So excited to see this dream team take on the @JCO_ASCO fellowship!! And excited to be a part of the journey as well. Congrats!! 🥳

[Michael Hughes @MSHughes_MD]

An honor and privilege to serve as a 2024-2025 @JCO_ASCO Editorial Fellow under the one and only @SLentzsch as my primary mentor--not just in the lab and the clinic--alongside my good friend @AlexandraRojek!

[Alexandra Rojek @AlexandraRojek]

It’s been an honor and such a phenomenal learning experience to be a @JCO_ASCO editorial fellow this past year along with @GCarvalho_MD @RohitBanwar and Subodh Selukar - grateful to have learned from @SLentzsch and @DrJFriedberg among so many others!! @ASCO #ASCO24